Global PARP Inhibitor Biomarkers Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for PARP Inhibitor Biomarkers Market is presumed to reach the market size of nearly USD 2020.32 Million by 2032 from USD 911.23 Million in 2023 with a CAGR of 9.25% under the study period 2024 - 2032.

PARP inhibitor biomarkers are molecular markers that identify cancer patients likely to respond positively to treatment with poly (ADP-ribose) polymerase (PARP) inhibitors. These biomarkers include genetic mutations or alterations in DNA repair pathways, such as BRCA1 and BRCA2 genes, and other genes associated with homologous recombination deficiency (HRD) or synthetic lethality. By analyzing these biomarkers through genetic testing or molecular profiling of tumor tissues, oncologists can determine the suitability of PARP inhibitor therapy for individual patients and tailor treatment strategies to maximize efficacy and minimize side effects in ovarian, breast, and prostate cancer.

MARKET DYNAMICS

The spurring understanding of cancer biology and the role of DNA damage repair pathways in cancer progression drive the growth of PARP inhibitors as a promising class of anticancer agents. With PARP inhibitors showing efficacy in treating cancers with specific genetic mutations such as BRCA1 and BRCA2, there is a growing need for biomarkers that can accurately predict patient response to PARP inhibitor therapy and identify individuals most likely to benefit from treatment. Additionally, the emergence of companion diagnostics and genomic profiling technologies enables the identification of biomarkers associated with PARP inhibitor sensitivity or resistance, facilitating patient stratification and treatment decision-making. Moreover, the increasing adoption of precision medicine approaches in oncology drives the demand for biomarker-driven therapies that target specific molecular pathways and tumor characteristics, minimizing treatment-related toxicity and maximizing therapeutic efficacy.

Furthermore, advancements in biomarker discovery technologies, including next-generation sequencing (NGS), gene expression profiling, and liquid biopsy assays, enable the identification of novel predictive biomarkers for PARP inhibitor response, expanding the potential patient population eligible for treatment. With pharmaceutical companies investing in developing PARP inhibitors and companion diagnostics, there is a growing need for biomarker validation studies and regulatory approval of biomarker-driven companion diagnostics for PARP inhibitor therapy. Additionally, the rising incidence of cancer and the increasing demand for personalized treatment options drive the market for PARP inhibitor biomarkers. However, advancements in cancer research, new treatment modalities, and evolving regulatory requirements may challenge the PARP Inhibitor Biomarkers market growth in the coming years as the landscape of cancer diagnostics and therapeutics continues to grow.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of parp inhibitor biomarkers. The growth and trends of parp inhibitor biomarkers industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the parp inhibitor biomarkers market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Kits
Assays

By Services

BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others

By Application

Breast Cancer
Ovarian Cancer
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the PARP Inhibitor Biomarkers market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the PARP Inhibitor Biomarkers market include Myriad Genetics, Inc., AmbryGenetics, Thermo Fisher Scientific Inc., Illumina, Inc., Centogene N.V., Amoy Diagnostics Co., Ltd., Invitae Corporation, NeoGenomics Laboratories., Qiagen, Agilent Technologies, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.'

Product Code: VMR112114327

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. PARP INHIBITOR BIOMARKERS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Services
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data
5.3. Analysis By Product
5.4. Kits Historic and Forecast Sales By Regions
5.5. Assays Historic and Forecast Sales By Regions

6. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY SERVICES

6.1. Overview By Services
6.2. Historical and Forecast Data
6.3. Analysis By Services
6.4. BRCA 1 & 2 Testing Historic and Forecast Sales By Regions
6.5. HRD Testing Historic and Forecast Sales By Regions
6.6. HRR Testing Historic and Forecast Sales By Regions
6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY APPLICATION

7.1. Overview By Application
7.2. Historical and Forecast Data
7.3. Analysis By Application
7.4. Breast Cancer Historic and Forecast Sales By Regions
7.5. Ovarian Cancer Historic and Forecast Sales By Regions
7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PARP INHIBITOR BIOMARKERS COMPANIES

9.1. PARP Inhibitor Biomarkers Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF PARP INHIBITOR BIOMARKERS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Myriad Genetics Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. AmbryGenetics
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Thermo Fisher Scientific Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Illumina Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Centogene N.V.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Amoy Diagnostics Co. Ltd.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Invitae Corporation
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. NeoGenomics Laboratories.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Qiagen
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Agilent Technologies Inc.
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies